Verum.de
(Verum), a full-clinical service, German-based contract research organization (CRO) with experience in Central and Eastern European countries (CEE), has opened a new office in Carlsbad, Calif. The company opened the office to make its
clinical trial services
more readily available to clients in the U.S. and North America. By conducting clinical trials with Verum in CEE countries, clients will benefit from faster patient enrollment, more affordable trials, and the ease of working with a CRO with regional expertise that practices Western standards for clinical trials and bridges cultural differences.
Kristi Clark will be managing the new U.S. office, in charge of day-to-day operations, new business acquisition, project management and marketing. Clark has experience in global project management and more than 20 years of pharma industry experience, having worked at both large and mid-size CROs, including Quintiles, Parexel and Synteract. Her prior experience included a nearly two year stay in the Czech Republic opening an office in Prague.
Verum, experienced in working with American pharma and biotech companies and as a sub-contractor to CROs not present in the CEE region, recently ran a U.S. government-sponsored trial and has received commendations for the high quality of its data from Columbia University. Verum can also assist with registering drugs for commercial use in CEE countries and provides full logistic service, something other CROs often cannot do. Verum has more than 100 office based employees operating out of eight locations, including its
Munich headquarters
, and everyone speaks English. Clients are also afforded the choice between U.S. or German based contracts. The company offers therapeutic specialties in cardiovascular, neurology, psychiatry, CNS, oncology and pain, among others.
“I founded this company on Western principles and our longevity is proof of our hard-work, diligence and attention to detail,” explained Christian Sacher, Verum CEO. “We are well-versed in running trials in Central and Eastern European and former Soviet bloc countries because in many cases we were the first to do so; our goal is to bring more client trials to CEE countries so they can see the
difference
faster enrollment and regional expertise provides.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.